Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Fourth Human Study for Reducing Hypertension, Reports Positive Outcome of Third Human Study’s Data
Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce…
